Chandan Kumar K N
Dr Chandan Kumar K N
  • MD (General Medicine)
  • DM (Hepatology)
16 Years
Language Spoken
Consultation Charges
Book Appointment


Dr Chandan Kumar has obtained his MBBS and MD (General Medicine) from Manipal University. He is the first qualified DM Hepatology from the prestigious Institute of Liver and Biliary Sciences (ILBS), New Delhi. He later received short training in Transplant Hepatology in Division of Liver Diseases, Mount Sinai Medical Center New York, US and in Liver Intensive Care, Institute of Liver Studies, Kings College Hospital London, UK.


He has more 16 years of experience in treating different types of liver diseases including jaundice, liver failure, cirrhosis, liver cancer and so on.

He is a member of several prestigious professional societies such as American College of Gastroenterology (ACG), American Association for Study of the liver diseases (AASLD), Asia- Pacific association for study of liver (APASL), International Liver Transplant Society (ILTS), Indian National Association for Study of Liver (INASL) and so on.


Areas of interest: acute-on-chronic liver failure, portal hypertension, transplant hepatology

Academic achievements: He has done pioneering work in role of granulocyte stimulating factor in liver disease, published over 50 original and review articles in various international and national peer-reviewed publications, reviewer for many journals, invited faculty in various national and international scientific forums.


MD (Gen Med), DM (Hepatology)


• 1. Kedarisetty CK, Vangara S. Early prediction of decompensation score (EPOD): A closer look! Gastroenterol Hepatol Endosc Pract 2023; 3: 170-1. DOI: 10.4103/ghep.ghep_8_23
2. Premkumar M, Kedarisetty CK, Moreau R. Preventive strategies for alcohol associated liver disease. Chapter in Preventive Hepatology 2023, Taylor and Francis
3. Kedarisetty CK, Vangara S, Prabhakar V. Probiotics role in liver disease – A magic bullet? Acta Scientific Gastro Dis 2023; 6 (8): 2-3. doi: 10.31080/ASGIS.2023.06.0545
4. Kedarisetty CK, Jain M, Selvan TS et al. Chapter on Infectious Diseases of the Liver. Book on Liver, Gallbladder and Bile Ducts 2023. Accepted for publication
5. Philips CA, Kedarisetty CK. Palliative care in End Stage Liver Disease Patients. J Clin Exp Hepatology 2023, 13(2): 319 - 323  
6. Yalaka R, Reddy K, Kedarisetty CK et al. Novel technique of cholangioscopy guided inwardly migrated biliary stent retrieval. Endoscopy 2023;55 (S 01):E996-997. doi: 10.1055/a-2127-5045
7. Kumar A, Sarin SK, …… Kedarisetty CK et al. Predictive scores for mortality in MAFLD related acute-on-chronic liver failure (MAFLD-ACLF): Development and validation of MAFLD-MELD Na scores and MAFLD-AARC scores. J Clin Exp Hepatology 2023; 13: S3-4. DOI:
8. Vangara S, Kedarisetty CK, Mogili KR et al. Comparative study of Gut Microbiome signatures in cirrhotics and thei healthy donors undergoing living donor liver transplantation. J Clin Exp Hepatol 2022; 12 (S2): S49 - 50 
9. Bhargav VY, Jain M, Alen T, Dorairaj D, Kedarisetty CK, Arthur P et al. Clusters and components of Metabolic Syndrome (MeS) as a predictor for fatty liver- a cross-sectional study. J Diabetol 2022; 12:434‐41
10. Kedarisetty CK, Kumar A, Sarin SK. Insights into Role of Granulocyte stimulating factor in severe alcoholic hepatitis. Semin Liv Dis 2021; 41(1):67-78;
11. Kedarisetty CK, Bhardwaj A, Kumar G et al. Efficacy of a Combination of Pentoxiphylline and Vitamin E versus Vitamin E alone in non-alcoholic steatohepatitis – A randomized pilot study. Indian J Gastroenterol 2021; 40: 41 – 49.
12. Kedarisetty CK, Bal S, Parida S et al. Role of N-acetyl cysteine in post TACE transaminitis in hepatocellular carcinoma – a single centre experience. J Clin Exp Hepatol 2021; 11(3): 299 - 304
13. Premkumar M, Kedarisetty CK. The Cytokine Storm of COVID-19 and its impact on patients with and without Chronic Liver Disease. J Clin Transl Hepatol 2021;
14. Varanasi BY, Kedarisetty CK, Mu K, Selvan TS, Venkataraman J. Dual or single risk factor in acute liver failure. Gastroenterol Hepatol Endosc Pract 2021; 1: 151-4
15. Bhadoria AS, Gawande KB, Kedarisetty CK et al. Estimating the proportion of prison inmates with chronic hepatitis B and hepatitis C infection in India: a systematic review and meta-analysis. Cureus 2021; 13(11): e19672.

16. Govindarajan R, Ramamoorthy G….Kedarisetty CK, Venkataraman J et al. Rodenticide ingestion is an important cause of acute hepatotoxicity in Tamil Nadu, Southern India. Indian J Gastroenterol 2021; 40 (4): 373 - 379
17. Malleswaran S, Mohanka R…. Kedarisetty CK, Varghese J, Reddy MS. Living donor hepatectomy after proven SARS – CoV-2 infection: First report of 9 cases from 3 centers. Transplantation 2021; 105 (7): e70-71.
18. Varghese J, Kedarisetty CK, Malleswaran S et al. A Multi-centric Experience on Living Donor Liver Transplantation in COVID - 19 Hotspots in India. Liver Transpl 2021; 27 (9): 1334 – 1338.

19. Varadharajan J, Kedarisetty CK et al. Acute Kidney Injury in a Patient treated with Tenofovir Alafenamide Fumarate for Hepatitis B Virus Infection. Saudi J Kidney Dis Transpl 2021; 32 (2): 592 - 594
20. Kedarisetty CK, Kumar R. An Unusual cause of severe and transfusion refractory anemia in patients with acute-on-chronic liver failure. Cureus 2020; 12(9): e10568;
21. Kedarisetty CK, Samaga B L, Vidyasagar S, Venkataraman J. Oral Melatonin improves the detection of parasitemia in malaria. J Infect Dev Ctries 2020; 14(11): 1327-1331.
22. Kedarisetty CK, Bhargav V, Karthikeyan M et al. Wilson's disease presenting as ACLF: A mystery yet to be solved!! J Clin Exp Hepatol 2020; 10(5): 529-530. 
23. Kedarisetty CK, Senthil Kumar MP, Bhargav V et al. Understanding the Basic Concepts of Liver Transplantation. Acta Scientific Gastro Dis 2020; 3 (2): 1- 9
24. Jain M, Kedarisetty CK, Selvan TS, Senthil Kumar MP, Venkataraman J. Does Gender matter in Liver Transplantation. Clinical Approach and Management Strategies of Medical Ailment in Women; Oorja – The Power of Her 2020
25. Kedarisetty CK, Bhargav V, Karthikeyan M et al. The predicament of the PREDICT study. J Clin Exp Hepatol 2020, 10(3):271. doi: 10.1016/j.jceh.2019.11.007
26. Kedarisetty CK, Sridhar A, Durairaj S et al. Predictors of abnormal and setting of normal values of AST and ALT for Indian population. J Gastroenterol Hepatol 2019;
27. Kedarisetty CK, Katukuri GR, Venkataraman J. Saline irrigation for residual CBD stones. Is it indicated for all? American J Gastroenterol 2019; 114 (3): 536, DOI: 10.14309/ajg.0000000000000094 
28. Kedarisetty CK, Kamble R, Joseph S, Venkataraman J. Management of Hepatopulmonary syndrome in a Child due to a Large Congenital Intrahepatic Porto-Systemic shunt. International J Gastroenterology 2019; 3(1): 23-26. doi: 10.11648/j.ijg.20190301.14  
29. Devarbhavi H, Choudhary A, Kedarisetty CK et al. Drug Induced Acute-on-chronic liver failure in Asian patients. American J Gastroenterol 2019; 114(6): 929-937
30. Bokarvadia R, Jain M, Kedarisetty CK et al. Prevalence and Clinical presentation of cirrhotic cardiomyopathy: A single center experience from southern India. Indian J Gastroenterol 2019; 38 (2): 150 - 157 
31. Sanglodkar U, Jain M, Kedarisetty CK, Varghese J, Venkataraman J. Clinical audit to determine the efficacy of daily infusion of low dose 20% albumin in combination with antibiotics in patients with spontaneous bacterial peritonitis. Clin Exp Hepatol 2019; 5(4):301-307  
32. Anand L, Bihari C, Kedarisetty CK, Rooge SB et al. Early cirrhosis and a preserved bone marrow niche favor regenerative response to growth factors in decompensated cirrhosis. Liver International 2018; doi: 10.1111/liv.13923
33. Bhadoria AS, Kedarisetty CK, Bhardwaj A et al. Positive family history for metabolic traits predisposes to early and more severe alcoholic cirrhosis: A cross-sectional study. Liver International 2018; doi:10.1111/liv.13958 
34. Bhadoria AS, Kedarisetty CK, Bihari C, Kumar G et al. Impact of family history of metabolic traits on severity of NASH related cirrhosis: a cross-sectional study. Liver International 2017; doi: 10.1111/liv.13396   
35. Varghese J, Kedarisetty CK, Venkataraman J, Srinivasan V et al. Combination of TACE and sorafenib improves outcomes in BCLC stages B/C of Hepatocellular carcinoma: A single center experience. Annals of Hepatology 2017; 16(2):247-254
36. Choudhary A, Kedarisetty CK, Vashishtha C et al. A randomised trial comparing terlipressin and noradrenaline in patients with septic shock. Liver International 2017; 37(4):552-561
37. Maiwall R, Sarin SK, Kumar S, Kedarisetty CK, Abbas Z et al. Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. Liver International 2017; doi: 10.1111/liv.13443 
38. Jain M, Varghese J, Kedarisetty CK, Balajee G et al. An insight into antibiotic resistance to bacterial infection in chronic liver disease. J Clin Exp Hepatol 2017; 7 (4): 305- 309 
39. Bhardwaj A, Kedarisetty CK, Vashishtha C, Bhadoria A et al. Carvedilol delays the progression of small esophageal varices in patients with cirrhosis. Gut 2016; doi: 10.1136/gutjnl-2016-311735 
40. Choudhary A, Bhardwaj A, Kedarisetty CK, Ilan Y, Sarin SK. Methacetin Breath test is superior to MELD in predicting mortality in acute-on-chronic liver failure: Results of a Phase-2 clinical trial. J Hepatol 2016; 64 (2): S228 
41. Kedarisetty CK, Anand L, Bhardwaj A et al. Combination of Granulocyte colony stimulating factor and Erythropoieitin improves outcome of patients with decompensated cirrhosis. Gastroenterology 2015 Jun;148(7):1362-1370
42. Rangegowda D, Sharma S, Kedarisetty CK, Maiwall R et al. Association between PNPLA3 L148M polymorphism and nonalcoholic fatty liver disease in the Indian subcontinent. J Hepatol 2015; 62 (2): S748  
43. Maras J, Maiwall R, Kedarisetty CK, Sharma S et al. Dysregulated iron homeostasis is strongly associated with multi-organ failure and early mortality in acute-on-chronic liver failure. Hepatology 2015 Apr;61(4):1306-20
44. Kedarisetty CK, Sarin SK, Anand L, Abbas Z et al. Liver failure determines the extra-hepatic organ failure and outcome in patients with acute-on-chronic liver failure: Analysis of 1363 patients of AARC database. Hepatology 2014, 60: 556A
45. Choudhary A, Kedarisetty CK, Vashishtha C, Sarin SK et al. Systemic inflammatory response syndrome (SIRS) — a potential clinical marker for early sepsis and survival in acute on chronic liver failure (ACLF). Hepatology 2014; 60 (Suppl. 1), A476A
46. Choudhary A, Kedarisetty CK, Wagle P et al. Predictors of Terlipressin related adverse effects in liver cirrhosis and its influence on survival. J Hepatol 2014; 60 (1): S16. doi:10.1016/S0168-8278(14)60040-4
47. Kedarisetty CK, Anand L, Khanam A, Kumar A, Rastogi A, Maiwall R, Sarin SK. Growth factors enhance liver regeneration in acute-on-chronic liver failure. Hepatology Int 2014; 8(2): 514- 525 
48. Kumar N, Kedarisetty CK, Kumar S, Khillan V, Sarin SK. Anti-tubercular therapy in patients with cirrhosis: Challenges and options. World J Gastroenterol 2014; 20(19): 5760–5772
49. Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D et al. Acute-on-chronic liver failure: An update on consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatology Int 2014; 8: 453- 471
50. Maiwall R, Kumar S, Choudhary A, Maras J, Wani Z, Kumar CK, Rastogi R et al. Serum ferritin predicts early mortality in patients with decompensated cirrhosis. J Hepatol 2014; 61 (1): 43- 50
51. Sarin SK, Kumar CK. Deeper insights into the relevance of lymphatic circulation in cirrhosis of liver- ‘A Trojan Horse or the Holy Grail’. Hepatology 2013; 58(6):2201-4 
52. Khanam A, Trehanpati N, Garg V, Kumar CK, Garg H, Sharma BC, Sarin SK. Altered frequencies of dendritic cells and IFN-γ secreting T cells with granulocyte colony stimulating factor (G-CSF) therapy in acute-on-chronic liver failure. Liver International 2014; 34(4): 505-13
53. Sarin SK, Kumar CK. Treatment of patients with genotype 3 chronic Hepatitis C- current and future therapies. Liver International 2012 Feb; 32 Suppl 1:141-5
54. Kumar R, Rastogi A, Sharma MK, Bhatia V, Tyagi P, Sharma P, Garg H, Kumar CK, Bihari C, Sarin SK. Liver Stiffness Measurements in Patients with Different Stages of Non-alcoholic Fatty Liver Disease: Diagnostic Performance and Clinico-pathological Correlation. Dig Dis Sci 2013 Jan; 58(1): 265-74 
55. Sarin SK, Kumar CK. Ectopic varices. Clinical liver disease 2012; 1(5): 168-172  
56. Ahuja A, Prabhat P, Rastogi A, Panda D, Kumar CK, Sarin SK. Extensive amyloid deposit in bone marrow aspirate. Indian J Hematol Blood Transfus. 2013;29(3):187-8
57. Premkumar M, Vyas T, Vashishtha C, Kumar CK , Rastogi A, Sharma P. Gall bladder adenoacarcinoma masquerading as dermatomyositis. Oncol Gastroenterol Hepatol Rep 2014; doi:10.4103/2348-3113.141587
58. Philips CA, Kalal CR, Kumar CK, Bihari C, Sarin SK. Simultaneous occurrence of ocular, disseminated mucocutaneous, and multivisceral involvement of leishmaniasis. Case Reports Infect Dis 2014; Article ID 837625
59. Philips CA, Anand L, Kumar CK, Kasana V, Arora A. Rare, spontaneous trans-splenic shunt and intra-splenic collaterals with attendant splenic artery aneurysms in an adult patient with compensated cirrhosis with portal hypertension. Gastroenterology Report 2014; 1–5, doi:10.1093/gastro/gou047
60. Philips CA, Kalal CR, Kumar CK, Bihari C, Sahney A, Rastogi A. Unique presentation of giant microcystic serous adenocarcinoma of the pancreas. Case Reports Gastro Med 2014; Article ID 913745
61. Philips CA, Anand L, Kumar CK. Symptomatic presentation of Intrahepatic portal vein aneurysm. ACG Case Rep J 2014; 2(1): 14 - 15  
62. Kedarisetty CK, Bhardwaj A, Jindal A et al. Carvedilol and Probiotic VSL#3 is not effective as Endoscopic variceal ligation for Primary Prophylaxis of Large esophageal varices in Carvedilol Non-responders- A RCT. Liver International 2020; in peer review

Latest from our blogs

View all
  • Hepatology
    Jul 26, 2023

    Is dark chocolate healthy for liver?

    Read more
  • Hepatology
    Feb 28, 2023

    What is Liver Inflammation? Causes and How to Treat It

    Read more

Need Help